 WALTHAM, Mass., Sept. 03, 2021 GLOBE NEWSWIRE -- Apellis Pharmaceuticals, Inc. Nasdaq: APLS, a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company approved the grant of equity awards to its newly appointed VP, Corporate Controller Chief Accounting Officer, Jim Chopas, with a grant date of August 30, 2021, as equity inducement awards outside of the companys 2017 Stock Incentive Plan but under the terms of the 2021 Inducement Stock Incentive Plan and material to Mr. Chopas entering into employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635c4. 